Primary lateral sclerosis (PLS) is a rare neurodegenerative disease that affects the upper motor neurons in the brain. These are the nerve cells responsible for sending movement signals from your brain down through the spinal cord to your muscles. As these neurons gradually deteriorate, muscles become increasingly stiff and difficult to control, leading to problems with walking, balance, coordination, and sometimes speech. PLS is often compared to ALS, but it progresses much more slowly and has a significantly better prognosis.
How PLS Affects the Body
Your nervous system uses two types of motor neurons to control voluntary movement. Upper motor neurons originate in the brain’s motor cortex and relay signals downward. Lower motor neurons pick up those signals in the spinal cord and deliver them directly to muscles. PLS selectively damages the upper motor neurons while leaving the lower motor neurons largely intact. This distinction is critical because it means PLS does not cause the severe muscle wasting and atrophy that defines ALS, where both sets of neurons break down.
What happens physically is a degeneration of the brain’s primary motor cortex and the nerve pathways (corticospinal tracts) that carry movement signals to the spinal cord. MRI studies show that the motor cortex in people with PLS is measurably thinner than in healthy individuals, averaging about 2.3 mm compared to 2.8 mm, while nearby brain regions like the sensory cortex remain normal. This selective loss of gray matter in the motor area confirms that PLS targets movement-specific neurons with unusual precision.
Early Symptoms and How They Progress
PLS typically begins between ages 40 and 60. The most common early symptoms are muscle stiffness, a sense of weakness, and cramps, usually showing up first as a change in how you walk. About 70% of people with PLS start with stiffness and weakness in both legs (the ascending paraparetic form). Around 21% begin on one side of the body, with symptoms starting in one arm or leg and spreading to the limb above or below on the same side. Roughly 9% start with bulbar symptoms, meaning speech and swallowing difficulties appear first.
The disease progresses slowly. In the most common leg-onset pattern, symptoms spread upward to the arms after a median of about 7 years, though the range is wide, from 1 to 26 years. This slow, ascending progression is one of the hallmarks that distinguishes PLS from faster-moving conditions. Over time, stiffness worsens, balance becomes more difficult, and fine motor tasks like writing or buttoning a shirt grow harder. Speech can become slurred and effortful as the muscles of the mouth and throat stiffen.
How PLS Differs From ALS
The most common concern after hearing about PLS is whether it might actually be ALS. The two diseases occupy related territory, but they differ in important ways. ALS attacks both upper and lower motor neurons, which causes not only stiffness but also muscle wasting, twitching (fasciculations), and rapid loss of muscle bulk. PLS, by contrast, causes stiffness and spasticity without significant wasting because the lower motor neurons that directly feed muscles are preserved.
The pace of the two diseases is also very different. ALS typically progresses over 3 to 5 years, while PLS unfolds over decades. Because there is no definitive lab test for PLS, doctors generally require that symptoms remain purely upper motor neuron in character for at least 4 years before confirming the diagnosis. If signs of lower motor neuron damage (like muscle wasting or specific patterns on nerve conduction tests) appear within that window, the diagnosis shifts toward ALS or an upper motor neuron-dominant form of ALS.
What Causes PLS
The exact cause of PLS is unknown in most cases. It is not considered a hereditary disease in the typical sense, but research has identified a genetic component in certain families. Juvenile-onset PLS, which is extremely rare and appears in childhood, has been linked to mutations in the genes ALS2 and ERLIN2. In adults, variants in the C9orf72 gene, which is also associated with ALS and frontotemporal dementia, have been found in some patients.
Researchers have also identified mutations in SPG7, a gene that codes for a protein involved in mitochondrial function, in at least one family with multiple affected members. These mutations are exceedingly rare and were not found in large databases of tens of thousands of healthy individuals. For most people diagnosed with PLS, no specific genetic cause can be identified, and the disease appears to arise sporadically.
How PLS Is Diagnosed
There is no single blood test or scan that confirms PLS. Diagnosis is primarily clinical, meaning it relies on a neurologist’s examination and the exclusion of other conditions that can look similar. The process typically involves MRI of the brain and spinal cord, nerve conduction studies, and electromyography (EMG) to check for lower motor neuron involvement. If EMG shows significant lower motor neuron damage, PLS becomes less likely and ALS more likely.
On MRI, the motor cortex may appear visibly thinner, particularly along the precentral gyrus (the ridge of brain tissue that houses the primary motor area). However, this thinning is not always dramatic enough to see on a standard scan, and no abnormal signal changes are typically visible along the nerve pathways. The diagnosis often takes years to confirm because doctors need to observe the disease’s behavior over time to be confident that lower motor neurons are not becoming involved.
Life Expectancy and Long-Term Outlook
PLS carries a far better prognosis than ALS. A large study using survival analysis found that the median disease duration from symptom onset was 23.1 years, and the median age at death was 79.5 years, compared to a general population average of 81.9 years. This means PLS is compatible with a near-normal lifespan. The trade-off is that the disease causes significant progressive physical disability over those decades, along with the mental and emotional toll that comes with it.
Most people with PLS will eventually need mobility aids. Many progress from a cane to a walker to a wheelchair over the course of years or decades. Speech can become increasingly difficult, and some individuals eventually need augmentative communication devices. Swallowing difficulties may develop but tend to be less severe than in ALS.
Treatment and Management
No disease-modifying treatment exists for PLS. As of 2025, there are no approved medications that slow or stop the progression of the disease, and no clinical trials are currently underway specifically for PLS. Management focuses entirely on controlling symptoms and maintaining quality of life for as long as possible.
Spasticity, the hallmark symptom, is typically managed with medications that reduce muscle stiffness. Baclofen and tizanidine are the most commonly used options. Both are effective at reducing stiffness, though they work somewhat differently. Baclofen tends to be more effective overall but is more likely to cause muscle weakness as a side effect. Tizanidine is more likely to cause drowsiness and dry mouth. Finding the right medication and dose often takes some trial and error, balancing stiffness relief against side effects.
Physical therapy plays a central role in PLS management. Regular stretching and range-of-motion exercises help combat the tightening of muscles and joints that comes with chronic spasticity. Gait training helps people maintain safe, independent walking for as long as possible. As the disease progresses, occupational therapy can help adapt daily tasks to changing abilities, and speech therapy can address slurred or effortful speech. For people who develop significant swallowing difficulties, a speech-language pathologist can recommend dietary modifications and swallowing strategies to reduce the risk of choking or aspiration.